节点文献

小分子靶向c-Fms抑制剂的研究进展

Progress in Small-Molecular Inhibitors Targeting c-Fms

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 王凯成张方青杨晓骏张惠斌周金培

【Author】 WANG Kaicheng;ZHANG Fangqing;YANG Xiaojun;ZHANG Huibin;ZHOU Jinpei;Department of Medicinal Chemistry, China Pharmaceutical University;

【通讯作者】 周金培;

【机构】 中国药科大学药物化学教研室

【摘要】 巨噬细胞集落刺激因子受体(c-Fms)是原癌基因fms编码的产物,为Ⅲ型酪氨酸激酶。c-Fms及其配体CSF-1在肿瘤相关巨噬细胞的增殖、生长、分化过程中起着重要作用。c-Fms在多种恶性肿瘤和炎性疾病中异常表达,CSF-1/c-Fms轴可能成为治疗恶性肿瘤的有效途径。许多以c-Fms为靶标的小分子抑制剂正在研究与临床开发中。简介c-Fms的结构特征和作用机制,对小分子靶向c-Fms抑制剂的研究进展进行综述,以期为相关研究提供参考。

【Abstract】 Macrophage colony stimulating factor receptor(c-Fms), the product encoded by proto-oncogene fms, is a type III receptor tyrosine kinase. c-Fms and its ligand CSF-1 play important roles in the proliferation, growth and differentiation of tumor-associated macrophages. c-Fms is abnormally expressed in a variety of malignant and inflammatory diseases. The CSF-1/c-Fms axis might be an effective approach to the treatment of malignant tumors. Many small molecular inhibitors targeting c-Fms are under research and clinical development. This article describes the mechanisms of c-Fms and its roles in tumor immunotherapy, and reviews the latest research progress in small-molecule inhibitors of c-Fms, so as to provide reference for follow-up studies.

  • 【文献出处】 药学进展 ,Progress in Pharmaceutical Sciences , 编辑部邮箱 ,2018年07期
  • 【分类号】R914
  • 【被引频次】1
  • 【下载频次】217
节点文献中: 

本文链接的文献网络图示:

本文的引文网络